Bulevirtide

Product NameBulevirtide
CAS2012558-47-1
CBNumberCB96185223
MW0
MOL FileMol file

Chemical Properties

form	Solid
color	White to off-white
FDA UNII	WKM56H3TLB
ATC code	J05AX28

Bulevirtide Chemical Properties,Usage,Production

Description

Bulevirtide (BLV), the first-in-class entry inhibitor, is a 47-amino acid synthetic liner lipopeptide derived from the preS1 domain of the HBV large surface that targets the NTCP, the entry receptor for HBV/HDV. By blocking this receptor, new infections are prevented, and infected hepatocytes are replaced by naive cells that will be protected from infection. Consequently, viral spread in the liver is prevented.

Biological Activity

The sequence of Bulevirtide (BLV) is derived from that of preS1 from HBV genotype C (residues Gly2-Gly48) with a shortening of the 11 additional N-terminal amino acids and one amino acid substitution, Gln46Lys. BLV exhibits a remarkably high inhibitory constant (IC50?=?140 pM) against HBV and HDV in primary human hepatocytes and HepaRG cells. BLV has also been demonstrated to inhibit the NTCP-mediated uptake of bile salts but at an IC50 in the nanomolar range[1].

References

[1] Liu, Hongtao et al. “Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.” Nature Communications 22 1 (2024).

Preparation Products And Raw materials

Bulevirtide Suppliers

Global(29)Suppliers

Region

China 26 United States 3

Clear All Done

Supplier	Tel	Email	Country	ProdList	Advantage
BOC Sciences	16314854226; +16314854226	inquiry@bocsci.com	United States	19741	58
Aladdin Scientific	+1-+1(833)-552-7181	sales@aladdinsci.com	United States	52924	58
Shenzhen Nexconn Pharmatechs Ltd	+86-755-89396905 +86-15013857715	admin@nexconn.com	China	10311	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10473	58
TargetMol Chemicals Inc.		support@targetmol.com	United States	38631	58
Zhejiang Hangyu API Co., Ltd	+8617531972939	anna@api-made.com	China	2943	58
Wuhan Jingkang en Biomedical Technology Co., Ltd	+8613720134139	orders@jknbiochem.com	China	5221	58
Changsha MOL Changes Biotechnology Co., Ltd.	+8619375158599	info@molchanges.com	China	5223	58
Shanghai EFE Biological Technology Co., Ltd.	021-65675885 18964387627	info@efebio.com	China	9806	58
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	8012	62

Bulevirtide: Pharmacodynamics, Pharmacokinetics and Adverse Events
Bulevirtide, effective against HBV and HDV, exhibits manageable adverse events, including increased bile salts. Close monitoring is needed for drug interactions.
Apr 22，2024

Bulevirtide:Application and safety

Bulevirtide, a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus and chronic hepatitis B virus infections.

Mar 29，2023